Inclusion Criteria:

- Signed informed consent.

- Women with a histologically/cytologically proven diagnosis of advanced adenocarcinoma
of the breast.

- Measurable disease. At least one unidimensionally measurable non-bony lesion with a
diameter >=10 mm using spiral CT scans (use of spiral CT must be documented in
medical records and used consistently throughout the study) or >= 20 mm using
conventional CT or MRI scans outside the irradiated area according to RECIST
criteria.

- Patients having failed both prior anthracycline and taxane derivative chemotherapy
regimens. Anthrocycline and Taxane failure definitions as defined in the protocol.

- No more than two prior chemotherapy regimens for advanced disease.

- Performance status (ECOG) <= 2 or Karnofsky >= 70

- Age >= 18 years.

- Life expectancy >= 12 weeks.

- Adequate organ function as shown by the following:

1. WBCs >= 3.0 x 109/L, absolute neutrophil count (ANC)>= 1.5 x 109/L, platelets >=
100 x 109/L, hemoglobin >= 9 g/dL

2. Bilirubin <= 1.25 x the upper limit of normal (ULN),aspartate
aminotransferase(AST or alanine aminotransferase(ALT),= 3 x ULN (or <= 5 x ULN
in case of liver metastases)

3. Serum calcium within normal limits

4. Serum albumin within the normal range for the study site

5. Creatinine clearance >= 60 mL/min (Cockroft and Gault)

6. Left ventricular ejection fraction (LVEF) within normal limits as shown by
echocardiography or scintigraphy (multiple-gated acquisition scan).

- Patients of childbearing potential must be using medically acceptable contraception
for 4 weeks before start of study treatment and 4 months after study treatment
completion. Patients of childbearing potential must have a negative pregnancy test
result within 7 days prior to study treatment initiation.

- Patients with parenchymal brain metastases must be either adequately controlled
following resection or completed appropriate radiation therapy and be receiving a
stable corticosteroid dose prior to study entry. Patients with leptomeningeal
involvement should not be included in the study.

Exclusion Criteria:

- Her2/neu positive tumor (2+ or 3+).

- Pregnancy or lactation

- Systemic cytotoxic anti-cancer therapy within <=4 weeks of study entry, or 6 weeks if
the systemic therapy contains a nitrosourea or mitomycin C. Hormonal anti-cancer
treatment must be ongoing, or must have been discontinued >3 months before study
entry.

- Prior 5-FU- and/or capecitabine-based palliative chemotherapy.

- Extensive prior radiotherapy affecting more than 30% of bone marrow reserves, or
bone marrow / stem cell transplantation.

- Participation in clinical studies of non-approved experimental agents or procedures
within <=4 weeks of study entry.

- History of other malignancy, unless cured and the patient has been disease-free for
>=2 years. Patients with a history of cervical carcinoma in situ or cured stage I
cervical cancer, or of epidermal or basal cell skin cancer, may be eligible for
enrollment after discussion with the sponsor.

- Previous unexpected reaction to fluoropyrimidines, with or without documented
deficiency of dihydropyrimidine dehydrogenase, or known hypersensitivity to 5-FU.

- Psychologic, familial, sociologic or geographic conditions which do not permit
compliance with the study protocol and/or study.

- Significant cardiac disease, including symptomatic ventricular arrhythmia, congestive
heart failure, myocardial infarction within 12 months before study entry.

- Concomitant treatment with any experimental drug or anti-cancer drug, except hormone
therapy or bisphosphonates.